100 related articles for article (PubMed ID: 19023539)
1. In vitro inhibitory potential of decursin and decursinol angelate on the catalytic activity of cytochrome P-450 1A1/2, 2D15, and 3A12 isoforms in canine hepatic microsomes.
Abd El-Aty AM; Shah SS; Kim BM; Choi JH; Cho HJ; Hee-Yi ; Chang BJ; Shin HC; Lee KB; Shimoda M; Shim JH
Arch Pharm Res; 2008 Nov; 31(11):1425-35. PubMed ID: 19023539
[TBL] [Abstract][Full Text] [Related]
2. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
3. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability.
Madgula VL; Avula B; Reddy V L N; Khan IA; Khan SI
Planta Med; 2007 Apr; 73(4):330-5. PubMed ID: 17372866
[TBL] [Abstract][Full Text] [Related]
4. Decursin and decursinol angelate selectively inhibit NADH-fumarate reductase of Ascaris suum.
Shiomi K; Hatano H; Morimoto H; Ui H; Sakamoto K; Kita K; Tomoda H; Lee EW; Heo TR; Kawagishi H; Omura S
Planta Med; 2007 Nov; 73(14):1478-81. PubMed ID: 17948169
[TBL] [Abstract][Full Text] [Related]
5. Decursinol angelate: a cytotoxic and protein kinase C activating agent from the root of Angelica gigas.
Ahn KS; Sim WS; Lee IK; Seu YB; Kim IH
Planta Med; 1997 Aug; 63(4):360-1. PubMed ID: 9270380
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 Isoforms in the Metabolism of Decursin and Decursinol Angelate from Korean Angelica.
Zhang J; Li L; Tang S; Hale TW; Xing C; Jiang C; Lü J
Am J Chin Med; 2015; 43(6):1211-30. PubMed ID: 26394652
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.
Yoo HH; Lee MW; Kim YC; Yun CH; Kim DH
Drug Metab Dispos; 2007 Oct; 35(10):1759-65. PubMed ID: 17620343
[TBL] [Abstract][Full Text] [Related]
8. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase.
Son SH; Kim MJ; Chung WY; Son JA; Kim YS; Kim YC; Kang SS; Lee SK; Park KK
Cancer Lett; 2009 Jul; 280(1):86-92. PubMed ID: 19307054
[TBL] [Abstract][Full Text] [Related]
9. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas.
Ahn KS; Sim WS; Kim IH
Planta Med; 1996 Feb; 62(1):7-9. PubMed ID: 8720379
[TBL] [Abstract][Full Text] [Related]
10. Decursinol and decursin protect primary cultured rat cortical cells from glutamate-induced neurotoxicity.
Kang SY; Kim YC
J Pharm Pharmacol; 2007 Jun; 59(6):863-70. PubMed ID: 17637179
[TBL] [Abstract][Full Text] [Related]
11. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450.
Shou M; Norcross R; Sandig G; Lu P; Li Y; Lin Y; Mei Q; Rodrigues AD; Rushmore TH
Drug Metab Dispos; 2003 Sep; 31(9):1161-9. PubMed ID: 12920172
[TBL] [Abstract][Full Text] [Related]
12. In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition.
Aidasani D; Zaya MJ; Malpas PB; Locuson CW
Drug Metab Dispos; 2008 Aug; 36(8):1512-8. PubMed ID: 18448570
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase.
Locuson CW; Ethell BT; Voice M; Lee D; Feenstra KL
Drug Metab Dispos; 2009 Mar; 37(3):457-61. PubMed ID: 19074522
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of plant secondary metabolite decursin by Mycobacterium sp. PYR1001.
Kim KY; Lee S; Cha CJ
J Agric Food Chem; 2010 Mar; 58(5):2931-4. PubMed ID: 20155945
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutical characterization of decursin and their derivatives for drug discovery.
Mahat B; Chae JW; Baek IH; Song GY; Song JS; Ma JY; Kwon KI
Drug Dev Ind Pharm; 2013 Oct; 39(10):1523-30. PubMed ID: 23003006
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes.
Kuroha M; Kuze Y; Shimoda M; Kokue E
Am J Vet Res; 2002 Jun; 63(6):900-5. PubMed ID: 12061540
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of pyranocoumarin isomers decursin and decursinol angelate by liver microsomes from man and rodents.
Li L; Zhang J; Xing C; Kim SH; Jiang C; Lü J
Planta Med; 2013 Nov; 79(16):1536-44. PubMed ID: 24026903
[TBL] [Abstract][Full Text] [Related]
18. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells.
Kim HH; Sik Bang S; Seok Choi J; Han H; Kim IH
Cancer Lett; 2005 Jun; 223(2):191-201. PubMed ID: 15896453
[TBL] [Abstract][Full Text] [Related]
19. Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats.
Li L; Zhang J; Xing C; Kim SH; Lü J
Planta Med; 2013 Mar; 79(3-4):275-80. PubMed ID: 23364885
[TBL] [Abstract][Full Text] [Related]
20. Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC.
Li L; Zhang J; Shaik AA; Zhang Y; Wang L; Xing C; Kim SH; Lü J
Planta Med; 2012 Feb; 78(3):252-9. PubMed ID: 22116603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
